Institutional Ownership
Xilio Therapeutics Inc
CUSIP 98422T100COMXLOQ1 2026
13D / 13G Filings
42
Schedule 13D/13G on record
Beneficial Filers
19
Distinct reporting persons
Largest Stake
19.9%
Max % of class reported
Institutional Holders
1
13F filers (latest quarter)
Beneficial Owners — Schedule 13D / 13G
42 filings · latest Feb 17, 2026
| # | Filed | Reporting Person | Form | % of Class | Shares | Filing |
|---|---|---|---|---|---|---|
| 1 | Feb 17, 2026 | Bain Capital Life Sciences Fund II, L.P. | 13G/A | 8.5% | 6.26M | SEC |
| 2 | Feb 17, 2026 | Stempoint Capital LP | 13G/A | 8.4% | 6.03M | SEC |
| 3 | Feb 13, 2026 | Frazier Life Sciences Public Fund, L.P. | 13G/A | 6.7% | 4.68M | SEC |
| 4 | Feb 12, 2026 | Gilead Sciences, Inc. | 13G/A | 19.9% | 14.52M | SEC |
| 5 | Dec 11, 2025 | Coastlands Capital LP | 13G | 10.0% | — | SEC |
| 6 | Nov 14, 2025 | Stempoint Capital LP | 13G | 7.2% | 4.00M | SEC |
| 7 | Nov 14, 2025 | Point72 Asset Management, L.P. | 13G/A | 9.9% | 8.00M | SEC |
| 8 | Aug 14, 2025 | Frazier Life Sciences Public Fund, L.P. | 13G/A | 9.9% | 8.14M | SEC |
| 9 | Aug 14, 2025 | Gilead Sciences, Inc. | 13G/A | 19.9% | 10.61M | SEC |
| 10 | Jun 17, 2025 | Point72 Asset Management, L.P. | 13G | 7.2% | 4.00M | SEC |
32 more beneficial-ownership filings on Premium
See the full Schedule 13D/13G history for Xilio Therapeutics Inc.
Unlock full historyTop Institutional Holders (13F)
Largest reported positions · latest quarter
| # | Fund | Shares | Value |
|---|---|---|---|
| 1 | Gilead Sciences, Inc. | 650.4K | $5.47M |